Table 11

Summary of ABT-116, carprofen, tramadol, and placebo treatment effects on dog mobility
Outcome measure ABT-116 Carprofen Tramadol Placebo
Significance ES Significance ES Significance ES Significance ES
CBPI questionnaire
Total CBPI score NS ** P < 0.005 ** P = 0.001 *** NS **
Pain Severity Score NS ** P < 0.005 ** NS ** NS **
Pain Interference Score NS ** P < 0.005 ** P < 0.001 *** NS **
Activity Monitoring
Total Activity NS * NS * NS *a NS *a
Daytime Activity NS * NS * NS *a NS *a
Nighttime Activity P ≤ 0.01 ** P ≤ 0.01 **a NS * NS *a
Kinetic Gait Analysis
Peak Vertical Force NS * NS * NS * NS *b
Vertical Impulse NS * NS ** NS *b NS **b
Falling Slope NS * NS * NS **c NS *c
Reduction in Use of Rescue Medication
P < 0.001 ** P < 0.001 ** NS ** NS **

Note: ES – effect size; CBPI – canine brief pain inventory questionnaire. ES magnitude is indicated by * - Small, ES ≤ 0.2; ** - Medium, ES = > 0.2 and < 0.8; *** - Large, ES ≥ 0.8. aES indicating reduction in dog activity. bES indicating reduction in peak vertical force or peak vertical impulse values. cES indicating falling slope is more negative after treatment (undesirable effect). NS – not significant.

Malek et al.

Malek et al. BMC Veterinary Research 2012 8:185   doi:10.1186/1746-6148-8-185

Open Data